Effectiveness and Safety Study of Fixed Versus Flexible of Gonadotropin-releasing Hormone Antagonist Protocol (GnRH)

December 16, 2015 updated by: Chong Qing Reproducive and Genetic Institute

A RCT Study to Evaluate the Safety and Efficacy of the Fixed Day-5 Antagonist Protocol Versus the Flexible Antagonist Protocol for the Controlled Ovarian Stimulation in Chinese Women With Predicted High Ovarian Response

The purpose of study is to compare the effectiveness of the Day-5 fixed administration of GnRH antagonist versus flexible administration of GnRH antagonist during ovarian stimulation in Chinese women with predicted high ovarian response, and the hypotheses is that the number of oocyte retrieved in fixed protocol is not inferior to GnRH antagonist flexible protocol.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

The investigator will be responsible for analyzing the study data. This study is designed as an open-label fashion, and thus, no blindness will be maintained during the study. The database will not be locked until medical/scientific review has been completed, protocol violators have been identified, and data has been declared complete.

Statistical Methods For the primary endpoint, mean and standard deviation (SD) on the number of oocytes will be presented. The between-group difference and corresponding 95% confidence interval (CI) (Day-5 fixed protocol - flexible protocol) will be calculated by using a two-sample t-test under the assumption that the sample data are normally distributed. A test for normality will be performed prior to the analysis on primary endpoint and possible nonparametric adjustment will be made for skewed data in terms of primary analyses. The non-inferiority will be established if the lower bound of the 95%CI in the treatment difference between two groups (Day-5 fixed protocol - flexible protocol) does not exceed -3.0. The superiority may be claimed for the Day-5 fixed protocol if the lower bound of 95%CI for the treatment difference is above 0.0.

For the secondary endpoints on categorical variables, the number and percentage of the event will be calculated and displayed. Clinical and ongoing pregnancy rates will be separately calculated and presented. Between-group comparisons will be made by Chi-square test and the corresponding 95%CI will be presented by using Miettinen-Nurminen method if the number of the observed events is at least 4. Mean and SD will be summarized for continuous variables in terms of secondary outcome measures. A treatment difference between study groups will be made by using two-sample t-test or nonparametric test whenever appropriate.

The number of subjects who have reported adverse experiences (AE) and the incidence of individual AEs will be counted and presented. Fisher's exact test will be performed to compare between treatment groups.

Demographics and the subject's relevant medical history will be summarized by descriptive statistics.

All statistical analyses will be two-sided and at a significant level of a p value less than 0.05, unless otherwise specified.

Sample Size:

A sample size of 200 (1:1 allocation) achieves 80% power to detect non-inferiority of the Day-5 fixed-dose regimen as compared with the flexible protocol by a margin at -3 oocytes retrieved (3 oocytes fewer than the controlled group), using a one-sided, two-sample t-test with Mann-Whitney test adjustment at the significance level at 0.025. The true difference between the means is assumed to be 0.0 and the standard deviation of both intervention arms to be 6.8. The pre-mature discontinuation rate is set at approximately 15% for this study.

Study Type

Interventional

Enrollment (Anticipated)

200

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 35 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  1. Have an indication for COS and IVF/ICSI;
  2. be <35 years old;
  3. have a BMI of 18-25kg/m2;
  4. have a regular menstruation with a range of 24-35 days;

  5. fulfill one of these three criteria as follow:

    • the number of oocytes retrieved>15 in previous COS cycle;
    • Serum AMH (examined on the menstrual cycle day 2)>3.52ng/ml;
    • antral follicle count (AFC) (examined by ultrasonic on the menstrual cycle day 2)>16
  6. have willingness to give informed consent

Exclusion Criteria:

  1. Presence of unilateral ovary absence;
  2. Any difficulty on oocyte pick-up with abnormal condition of ovary and pelvic cavity;
  3. Women have any clinically relevant pathology could impair embryo implantation or pregnancy continuation (uterine malformation, intermural uterine fibroids>3cm, intrauterine adhesion,etc);
  4. Women with polycystic ovary syndrome (PCOS) diagnosed by Rotterdam consensus criterion(Rotterdam, 2004)
  5. Other known abnormal ovulation disorders (including but not limited to adrenal gland disease, thyroid disease and hyperprolactinemia);
  6. A history of recurrent miscarriage or previous IVF cycles failure>2;
  7. A history of ovarian hypo-response in previous ovarian stimulation;
  8. Women with other clinical/socio-economic factors precluding the completion of the study at the discretion of the investigator.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Fixed Protocol
Patients will start Follitropin beta stimulation on menstrual cycle day 3 and the daily dose will be fixed for the first 5 days of stimulation, a modification of the rFSH dose will be allowed from stimulation day 6 onward. Ganirelix will start fixedly on stimulation Day 5. rhCG will be administered to induce final oocyte maturation as soon as at least three follicles of ≥17 mm were observed, and triptorelin trigger will be used as a replacement in case of OHSS high risk
Drug: Follitropin Beta
Patients will start stimulation with a daily s.c. injection of 150IU follitropin beta on menstrual cycle day 3. A modification of the rFSH dose will be allowed from stimulation day 6 onward in case that a high ovarian response occurs at the discretion of the investigator.
Other Names:
  • Puregon
Drug: Ganirelix
Ganirelix 0.25mg daily s.c. will start after 4 days of rFSH stimulation
Other Names:
  • Orgalutran
Drug: Ganirelix
Ganirelix 0.25mg daily s.c. will start when at least one of the following criteria are fulfilled: (i) the presence of at least one follicle measuring≥12 mm; (ii) serum E2 levels>600 pg/ml; and (iii) serum LH levels>10 IU/l.
Other Names:
  • Orgalutran
Drug: rhCG
An amount of 250ug rhCG will be administered to induce final oocyte maturation as soon as at least three follicles of ≥17 mm were observed
Other Names:
  • Ovidrel
Drug: triptorelin
0.2mg triptorelin will replace rHCG to trigger in case of high risk of overstimulation
Other Names:
  • Decapeptyl
Other: Flexible protocol
Patients will start Follitropin beta stimulation on menstrual cycle day 3 and the daily dose will be fixed for the first 5 days of stimulation, a modification of the rFSH dose will be allowed from stimulation day 6 onward. Ganirelix will start flexibly by the promissory criterion in the flexible group. rhCG will be administered to induce final oocyte maturation as soon as at least three follicles of ≥17 mm were observed, and triptorelin trigger will be used as a replacement in case of OHSS high risk
Drug: Follitropin Beta
Patients will start stimulation with a daily s.c. injection of 150IU follitropin beta on menstrual cycle day 3. A modification of the rFSH dose will be allowed from stimulation day 6 onward in case that a high ovarian response occurs at the discretion of the investigator.
Other Names:
  • Puregon
Drug: Ganirelix
Ganirelix 0.25mg daily s.c. will start after 4 days of rFSH stimulation
Other Names:
  • Orgalutran
Drug: Ganirelix
Ganirelix 0.25mg daily s.c. will start when at least one of the following criteria are fulfilled: (i) the presence of at least one follicle measuring≥12 mm; (ii) serum E2 levels>600 pg/ml; and (iii) serum LH levels>10 IU/l.
Other Names:
  • Orgalutran
Drug: rhCG
An amount of 250ug rhCG will be administered to induce final oocyte maturation as soon as at least three follicles of ≥17 mm were observed
Other Names:
  • Ovidrel
Drug: triptorelin
0.2mg triptorelin will replace rHCG to trigger in case of high risk of overstimulation
Other Names:
  • Decapeptyl

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
the number of oocytes retrieved
Time Frame: 3 weeks
3 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Total dosage of Gn and GnRH antagonist
Time Frame: 3 weeks
3 weeks
The incidence of premature LH surge during the stimulation
Time Frame: 3 weeks
3 weeks
The incidence of OHSS during the study
Time Frame: 5 weeks
5 weeks
The implantation rate
Time Frame: 5 weeks
the implantation rate is defined as the number of gestational sac observed by ultrasound examination at 4 weeks after ET per 100 embryos transferred
5 weeks
clinical pregnancy rate
Time Frame: 6 weeks
Clinical pregnancy was defined as the presence of a gestation sac with a positive heartbeat detectable by transvaginal ultrasonography at 6 weeks after ET.
6 weeks
ongoing pregnancy rate
Time Frame: 14 weeks
Ongoing pregnancy was defined as a pregnancy with cardiac activity proceeding beyond 12 weeks of gestation.
14 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Chong Qing Reproducive and Genetic Institute

Collaborators

Merck Sharp & Dohme LLC

Investigators

  • Study Director: Hong Ye, bachelor, Genetic and Reproductive Institute, Chongqing Obstetrics and Gynecology Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2016

Primary Completion (Anticipated)

December 1, 2016

Study Completion (Anticipated)

March 1, 2017

Study Registration Dates

First Submitted

December 11, 2015

First Submitted That Met QC Criteria

December 16, 2015

First Posted (Estimate)

December 21, 2015

Study Record Updates

Last Update Posted (Estimate)

December 21, 2015

Last Update Submitted That Met QC Criteria

December 16, 2015

Last Verified

December 1, 2015

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Merck-IISP-01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Infertility

Clinical Trials on Follitropin Beta

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Africa

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe